Mechanisms of illness during respiratory syncytial virus infection: The lungs, the virus and the immune response

Microbes and Infection

Volumn 6, Issue 8, 2004, Pages 767-772

  Hoffman, Scott J ^a,b   Laham, Federico R ^a,d   Polack, Fernando P ^a,b,c,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d Fundacion INFANT   (Argentina)

Author keywords

Immune response; Pathogenesis; Respiratory syncytial virus

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CHEMOKINE; INTERFERON; LIVE VACCINE; RECOMBINANT VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; VIRUS ANTIBODY;

ANTIVIRAL ACTIVITY; CELL CULTURE; DISEASE SEVERITY; GENE STRUCTURE; HOSPITALIZATION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INFLAMMATORY DISEASE; LOWER RESPIRATORY TRACT INFECTION; LUNG INFECTION; METAPNEUMOVIRUS; MORBIDITY; MORTALITY; NONHUMAN; PATHOGENESIS; PNEUMOVIRINAE; PRIMARY INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT DISEASE; REVIEW; SUPERINFECTION; VIRUS INFECTION; VIRUS REPLICATION; WILD TYPE;

RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

EID: 2942682827     PISSN: 12864579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.micinf.2004.03.010     Document Type: Short Survey

References (61)

1. Collins P.L., Chanock R.M., Murphy B.R. Respiratory syncytial virus disease. 4th edition Knipe D., Howley P. Fields in virology. 2001;1443-1486
2. Simoes E. Respiratory syncytial virus infection. Lancet. 354:1999;847-852
3. Altman C.A., Englund J.A., Demmler G., Drescher K.L., Alexander M.A., Watrin C., Feltes T.F. Respiratory syncytial virus in patients with congenital heart disease: a contemporary look at epidemiology and success of preoperative screening. Pediatr. Cardiol. 21:2000;433-438
4. Groothuis J.R. Role of antibody and use of respiratory syncytial virus (RSV) immune globulin to prevent severe RSV disease in high-risk children. J. Pediatr. 124:1994;S28-S32
5. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 102:1998;531-537
6. Gasparoni A., Ciardelli L., Avanzini A., Castellazzi A.M., Carini R., Rondini G., Chirico G. Age-related changes in intracellular TH1/TH2 cytokine production, immunoproliferative T lymphocyte response and natural killer cell activity in newborns, children and adults. Biol. Neonate. 84:2003;297-303
7. Martinez F.D., Wright A.L., Taussig L.M., Holberg C.J., Halonen M., Morgan W.J. Asthma and wheezing in the first six years of life. The Group Health Medical Associates. N. Engl. J. Med. 332:1995;133-138
8. Aherme W., Bird T., Court S.D.M., et al. Pathological changes in virus infections of the lower respiratory tract in children. J. Clin. Pathol. 23:1970;7-18
9. Murphy B.R., Collins P.L. Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics. J. Clin. Invest. 110:2002;21-27
10. Wright P.F., Karron R.A., Belshe R.B., et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J. Infect. Dis. 182:2000;1331-1342
11. Schmidt A.C., Wenzke D.R., McAuliffe J.M., St. Claire M., Elkins W.R., Murphy B.R., Collins P.L. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone. J. Virol. 76:2002;1089-1099
12. Teng M.N., Whitehead S.S., Bermingham A., St. Claire M., Elkins W.R., Murphy B.R., Collins P.L. Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees. J. Virol. 74:2000;9317-9321
13. Johnson T.R., Hong S., Van Kaer L., Koezuka Y., Graham B.S. NK T cells contribute to expansion of CD8(+) T cells and amplification of antiviral immune responses to respiratory syncytial virus. J. Virol. 76:2002;4294-4303
14. Garcin D., Curran J., Kolakofsky D. Sendai virus C proteins must interact directly with cellular components to interfere with interferon action. J. Virol. 74:2000;8823-8830
15. Young D.F., Didcock L., Goodbourn S., Randall R.E. Paramyxoviridae use distinct virus-specific mechanisms to circumvent the interferon response. Virology. 269:2000;383-390
16. Buchholz U.J., Finke S., Conzelmann K.K. Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV promoter. J. Virol. 73:1999;251-259
17. Chomaitree T., Roberts N.J. Jr, Douglas R.G. Jr, Hall C.B., Simons R.L. Interferon production by human mononuclear leukocytes: differences between respiratory syncytial virus and influenza viruses. Infect. Immun. 32:1991;300-303
18. Krilov L.R., Hendry R.M., Godfrey E., McIntosh K. Respiratory syncytial virus infection of peripheral blood monocytes: correlation with aging of cells and interferon production in vitro. J. Gen. Virol. 68:1987;1748-1753
19. Hall C.B., Douglas R.G., Simons R.L., Geiman J.M. Interferon production in children with respiratory syncytial, influenza and parainfluenza virus infections. J. Pediatr. 93:1978;28-32
20. McIntosh K. Interferon in nasal secretions from infants with viral respiratory tract infections. J. Pediatr. 93:1978;33-36
21. Whitehead S.S., Bukreyev A., Teng M.N., Firestone C.Y., St. Claire M., Elkins W.R., Collins P.L., Murphy B.R. Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees. J. Virol. 73:1999;3438-3442
22. Beutler B. TLR4 as the mammalian endotoxin sensor. Curr. Top. Microbiol. Immunol. 270:2002;109-203
23. Kurt-Jones E.A., Popova L., Kwinn L., Haynes L.M., Jones L.P., Tripp R.A., Walsh E.E., Freeman M.W., Golenbock D.T., Anderson L.J., Finberg R.W. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat. Immunol. 1:2000;398-401
24. Haynes L.M., Moore D.D., Kurt-Jones E.A., Finberg R.W., Anderson L.J., Tripp R.A. Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virus. J. Virol. 75:2001;10730-10737
25. Haeberle H.A., Takizawa R., Casola A., Brasier A.R., Dieterich H.J., Van Rooijen N., Gatalica Z., Garofalo R.P. Respiratory syncytial virus-induced activation of nuclear factor-kappaB in the lung involves alveolar macrophages and toll-like receptor 4-dependent pathways. J. Infect. Dis. 186:2002;1199-1206
26. Laham F.R., Israele V., Casellas J.M., et al. Differential production of inflammatory cytokines between primary infection with human metapneumovirus and other common respiratory viruses of infancy. J. Infect. Dis. 189:2004;2047-2056
27. Zhang Y., Luxon B.A., Casola A., Garofalo R.P., Jamaluddin M., Brasier A.R. Expression of respiratory syncytial virus-induced chemokine gene networks in lower airway epithelial cells revealed by cDNA microarrays. J. Virol. 75:2001;9044-9058
28. Casola A., Garofalo R.P., Haeberle H., Elliott T.F., Lin R., Jamaluddin M., Brasier A.R. Multiple cis regulatory elements control RANTES promoter activity in alveolar epithelial cells infected with respiratory syncytial virus. J. Virol. 75:2001;6428-6439
29. John A.E., Berlin A.A., Lukacs N.W. Respiratory syncytial virus-induced CCL5/RANTES contributes to exacerbation of allergic airway inflammation. Eur. J. Immunol. 33:2003;1677-1685
30. Noah T.L., Ivins S.S., Murphy P., Kazachkova I., Moats-Staats B., Henderson F.W. Chemokines and inflammation in the nasal passages of infants with respiratory syncytial virus bronchiolitis. Clin. Immunol. 104:2002;86-95
31. Thomas L.H., Friedland J.S., Sharland M., Becker S. Respiratory syncytial virus-induced RANTES production from human bronchial epithelial cells is dependent on nuclear factor-kappa B nuclear binding and is inhibited by adenovirus-mediated expression of inhibitor of kappa B alpha. J. Immunol. 161:1998;1007-1016
32. Oh J.W., Lee H.B., Park I.K., Kang J.O. Interleukin-6, interleukin-8, interleukin-11 and interferon-gamma levels in nasopharyngeal aspirates from wheezing children with respiratory syncytial virus or influenza A virus infection. Pediatr. Allergy Immunol. 13:2002;350-356
33. Gern J.E., Martin M.S., Anklam K.A., Shen K., Roberg K.A., Carlson-Dakes K.T., Adler K., Gilbertson-White S., Hamilton R., Shult P.A., Kirk C.J., Da Silva D.F., Sund S.A., Kosorok M.R., Lemanske R.F. Jr. Relationships among specific viral pathogens, virus-induced interleukin-8, and respiratory symptoms in infancy. Pediatr. Allergy Immunol. 13:2002;386-393
34. Noah T.L., Becker S. Chemokines in nasal secretions of normal adults experimentally infected with respiratory syncytial virus. Clin. Immunol. 97:2000;43-49
35. Jaovisidha P., Peeples M.E., Brees A.A., Carpenter L.R., Moy J.N. Respiratory syncytial virus stimulates neutrophil degranulation and chemokine release. J. Immunol. 163:1999;2816-2820
36. Bont L., Heijnen C.J., Kavelaars A., van Aalderen W.M., Brus F., Draaisma J.T., Geelen S.M., van Vught H.J., Kimpen J.L. Peripheral blood cytokine responses and disease severity in respiratory syncytial virus bronchiolitis. Eur. Respir. J. 14:1999;144-149
37. Hull J., Thomson A., Kwiatkowski D. Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families. Thorax. 55:2000;1023-1027
38. Harrison A.M., Bonville C.A., Rosenberg H.F., Domachowske J.B. Respiratory syncytial virus-induced chemokine expression in the lower airways: eosinophil recruitment and degranulation. Am. J. Respir. Crit. Care Med. 159:1999;1918-1924
39. Olszewska-Pazdrak B., Casola A., Saito T., Alam R., Crowe S.E., Mei F., Ogra P.L., Garofalo R.P. Cell-specific expression of RANTES, MCP-1 and MIP-1alpha by lower airway epithelial cells and eosinophils infected with respiratory syncytial virus. J. Virol. 72:1998;4756-4764
40. Haeberle H.A., Kuziel W.A., Dieterich H.J., Casola A., Gatalica Z., Garofalo R.P. Inducible expression of inflammatory chemokines in respiratory syncytial virus-infected mice: role of MIP-1alpha in lung pathology. J. Virol. 75:2001;878-890
41. Garofalo R.P., Patti J., Hintz K.A., Hill V., Ogra P.L., Welliver R.C. Macrophage inflammatory protein-1alpha (not T helper type 2 cytokines) is associated with severe forms of respiratory syncytial virus bronchiolitis. J. Infect. Dis. 184:2001;393-399
42. Tripp R.A., Jones L.P., Haynes L.M., Zheng H., Murphy P.M., Anderson L.J. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat. Immunol. 2:2001;732-738
43. Tripp R.A., Dakhama A., Jones L.P., Barskey A., Gelfand E.W., Anderson L.J. The G glycoprotein of respiratory syncytial virus depresses respiratory rates through the CX3C motif and substance P. J. Virol. 77:2003;6580-6584
44. Tripp R.A., Moore D., Winter J., Anderson L.J. Respiratory syncytial virus infection and G and/or SH protein expression contribute to substance P, which mediates inflammation and enhanced pulmonary disease in BALB/c mice. J. Virol. 74:2000;1614-1622
45. Tripp R.A., Moore D., Jones L., Sullender W., Winter J., Anderson L.J. Respiratory syncytial virus G and/or SH protein alters Th1 cytokines, natural killer cells and neutrophils responding to pulmonary infection in BALB/c mice. J. Virol. 73:1999;7099-7107
46. Openshaw P.J. Immunity and immunopathology to respiratory syncytial virus, the mouse model. Am. J. Respir. Crit. Care Med. 152:1995;S59-S62
47. Graham B.S. Immunological determinants of disease caused by respiratory syncytial virus. Trends Microbiol. 4:1996;290-293
48. Graham B.S. Pathogenesis of respiratory syncytial virus vaccine-augmented pathology. Am. J. Respir. Crit. Care Med. 152:1995;S63-S66
49. Kim H.W., Canchola J.G., Brandt C.D., Pyles G., Chanock R.M., Jensen K., Parrott R.H. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89:1969;422-434
50. Prince G.A., Curtis S.J., Yim K.C., Porter D.D. Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J. Gen. Virol. 82:2001;2881-2888
51. Connors M., Kulkarni A.B., Firestone C.Y., Holmes K.L., Morse H.C. III, Sotnikov A.V., Murphy B.R. Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells. J. Virol. 66:1992;7444-7451
52. Connors M., Giese N.A., Kulkarni A.B., Firestone C.Y., Morse H.C. III, Murphy B.R. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J. Virol. 68:1994;5321-5325
53. Graham B.S., Henderson G.S., Tang Y.W., Lu X., Neuzil K.M., Colley D.G. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J. Immunol. 151:1993;2032-2040
54. Polack F.P., Teng M.N., Collins P.L., Prince G.A., Exner M., Regele H., Lirman D.D., Rabold R., Hoffman S.J., Karp C.L., Kleeberger S.R., Wills-Karp M., Karron R.A. A role for immune complexes in enhanced respiratory syncytial virus disease. J. Exp. Med. 196:2002;859-865
55. Welliver R.C., Wong D.T., Sun M., Middleton E. Jr, Vaughan R.S., Ogra P.L. The development of respiratory syncytial virus-specific IgE and the release of histamine in nasopharyngeal secretions after infection. N. Engl. J. Med. 305:1981;841-856
56. Hancock G.E., Scheuer C.A., Sierzega R., Pryharski K.S., McBride J.T., Watelet L.F., Tebbey P.W., Smith J.D. Adaptive immune responses of patients with asthma to the attachment (G) glycoprotein of respiratory syncytial virus. J. Infect. Dis. 184:2001;1589-1593
57. Sparer T.E., Matthews S., Hussell T., Rae A.J., Garcia-Barreno B., Melero J.A., Openshaw P.J. Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia. J. Exp. Med. 187:1998;1921-1926
58. Srikiatkhachorn A., Braciale T.J. Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. J. Exp. Med. 186:1997;421-432
59. Choi E.H., Lee H.J., Yoo T., Chanock S.J. A common haplotype of interleukin-4 gene IL4 is associated with severe respiratory syncytial virus disease in Korean children. J. Infect. Dis. 186:2002;1207-1211
60. Hoebee B., Rietveld E., Bont L., Oosten M., Hodemaekers H.M., Nagelkerke N.J., Neijens H.J., Kimpen J.L., Kimman T.G. Association of severe respiratory syncytial virus bronchiolitis with interleukin-4 and interleukin-4 receptor alpha polymorphisms. J. Infect. Dis. 187:2003;2-11
61. Valarcher J.F., Furze J., Wyld S., Cook R., Conzelmann K.K., Taylor G. Role of alpha/beta interferons in the attenuation and immunogenicity of recombinant bovine respiratory syncytial viruses lacking NS proteins. J. Virol. 77:2003;8426-8439